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StructureConformational thermostabilisation of G protein-coupled receptors is a successful approach for their struc-
ture determination. We have recently determined the structure of a thermostabilised neurotensin receptor
NTS1 in complex with its peptide agonist and here we describe the strategy for the identiﬁcation and combi-
nation of the 6 thermostabilising mutations essential for crystallisation. First, thermostability assays were
performed on a panel of 340 detergent-solubilised Ala/Leu NTS1 mutants and the best 16 thermostabilising
mutations were identiﬁed. These mutations were combined pair-wise in nearly all combinations (119 out
of a possible 120 combinations) and each mutant was expressed and its thermostability was experimentally
determined. A theoretical stability score was calculated from the sum of the stabilities measured for each
double mutant and applied to develop 24 triple mutants, which in turn led to the construction of 14 quadru-
ple mutants. Use of the thermostability data for the double mutants to predict further mutant combinations
resulted in a greater percentage of the triple and quadruple mutants showing improved thermostability than
if only the thermostability data for the single mutations was considered. The best quadruple mutant
(NTS1-Nag36k) was further improved by including an additional 2 mutations (resulting in NTS1-GW5)
that were identiﬁed from a complete Ala/Leu scan of Nag36k by testing the thermostability of the mutants
in situ in whole bacteria. NTS1-GW5 had excellent stability in short chain detergents and could be readily pu-
riﬁed as a homogenous sample that ultimately allowed crystallisation and structure determination.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The rate of structure determination of G protein-coupled receptors
(GPCRs) has dramatically increased over the last 5 years. Initially,
only bovine rhodopsin yielded crystals sufﬁciently well-ordered to
allow high-resolution structures to be solved [1–4], but as of August
2012, the structures of 15 other GPCRs have been determined, in
complex with agonists, antagonists, antibodies, and/or heterotrimeric
G protein [5]. One of the key factors that allowed their crystallisation
was the development of techniques that stabilise the receptor either
during the crystallisation process or from an earlier stage by direct
thermostabilisation of the receptor in a speciﬁc conformation [6–8].ammer),
Granta Park, Cambridge CB21
h Institute, National Institutes
thesda, Maryland 20892, USA.
cine, Price Center, New York
rights reserved.If the GPCR is stabilised by a tightly-bound ligand that locks it in a sin-
gle conformation, then crystallisation of GPCR fusion proteins is pos-
sible in cholesterol-rich lipidic cubic phase, with the cholesterol
providing additional stability to the receptor [9]. This strategy has
proven successful for both aminergic and peptidergic receptors such
as the β2-adrenergic receptor (β2AR) [10], the adenosine A2A receptor
(A2AR) [11], and the opioid receptors [12–15]. In contrast, addition
of thermostabilising mutations, but not gene fusions, was essential
for the crystallisation of β1AR and A2AR in highly destabilising de-
tergents such as octylthioglucoside, Hega-10 or nonylglucoside
[16–21]. Thermostabilisation of a GPCR in the presence of an ago-
nist or antagonist changes the equilibrium between the different
conformations of the receptor, resulting in the stabilisation of either an
agonist-bound state or an antagonist-bound state [19,22–24]. When
this is performed on the same receptor, then themutations that stabilise
each conformation are quite distinct with only a small overlapping pop-
ulation that stabilises the receptor in both conformations [23]. The ad-
vantage of using thermostabilised receptors for crystallisation is that
they are stabilised preferentially in a single conformation and this allows
structure determination in a complex with low-afﬁnity ligands that
do not themselves signiﬁcantly stabilise the receptor, such as the
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bound to caffeine [21] or adenosine [16].
Although the advantages of having a thermostabilisedGPCR for struc-
tural and biophysical analysis are clear, the generation of suchmutants is
time consuming. It is true that once a thermostabilised receptor is pro-
duced the mutations can be transferred en bloc to members within the
same family [25], resulting in their thermostabilisation, but this does
not work for distantly related receptors as is evident from the apparent
lack of conservation of the thermostabilising mutations across multiple
receptor families. Thus anything that helps the efﬁcient generation of
the thermostabilised receptors would be advantageous. We have there-
fore studied themost difﬁcult step in the thermostabilisation procedure,
namely combining the single thermostabilising mutations to make an
optimally stable receptor. The target we have chosen for this study is
theneurotensin receptor, NTS1 [26]. Previously,we had developed amu-
tant, NTS1-7m, that was signiﬁcantly more stable than the wild-type
receptor in both the unliganded state and with neurotensin bound
[22]. Unfortunately, NTS1-7m had a strong tendency to aggregate upon
puriﬁcation and therefore was unsuitable for crystallisation. This may
have been at least partly because we generated an NTS1 mutant that
was stable both in the presence and absence of NT, choosing combina-
tions from mutations that stabilised both the unliganded state and the
agonist-bound state. In the work described here, we re-designed the
screening procedure and made extensive systematic combinations of
mutations, which stabilised NTS1 in the agonist-bound form, whilst ig-
noringmutations that stabilised NTS1 in the unliganded form. The stabil-
ity of one of the resulting quadruple mutants was further improved by
including 2 additional mutations, generating an ultra-stable neurotensin
receptor. The structure of thermostablised NTS1 fused to T4 lysozyme
was recently determined from material produced in insect cells [27].2. Materials and methods
2.1. Expression of NTS1 in Escherichia coli
Bacterial expression plasmids encoding the NTS1 fusion proteins
consisted of the E. coli maltose binding protein (MBP) with its signal
peptide, followed by the N-terminally truncated rat NTS1 (starting
at T43) and a C-terminal afﬁnity tag [28]. The various expression con-
structs used in this study are listed in Table 1. The NTS1 fusion pro-
teins were produced in E. coli as described [22,28]. Thermostable
mutants were harvested (2 ml aliquots) either 24 h (Nag mutants)
or 40 h after induction (Nag36k and GW5 derivatives). The name
“Nag” of the single, double, triple and quadruple mutants is derived
from “NTS1 thermostabilised in an agonist-bound state”. All the NagTable 1
Bacterial NTS1 expression constructs. SP-MBP, E. coli maltose-binding protein (K1-T366) p
protease recognition site; N10, deca-asparagine linker; H10, deca-histidine tag; inner loo
A86L–E166A–L310A–V360A; GW5, NTS1 with the thermostabilising mutations A86L–
one-letter code. Note that NTS1 starts in all constructs at T43. Construct details such as the
number code for the Nag36k and GW5 mutant series, respectively. See references [22] and
Construct ID N-terminal fusion Linker ICL3 mo
Wild-type NTS1
(624) SP-MBP GS None
All Nag derivatives
(624)Nag SP-MBP GS None
Nag36k derivatives (A86L, E166A, L310A, and V360A)
(624)Nag36k SP-MBP GS none
(1937B)Nag36k SP-MBP GS Δi3
(1937A)Nag36k SP-MBP GS-N10-ENLYFQS-GS Δi3
(2088)Nag36k SP-MBP GS-N10-ENLYFQS-GS Δi3
GW5 derivatives (A86L, E166A, G215A, L310A, F358A, and V360A)
(1937B)GW5 SP-MBP GS Δi3
(2088)GW5 SP-MBP GS-N10-ENLYFQS-GS Δi3
(2132)GW5 SP-MBP GS-N10-ENLYFQS-GS nonemutants were made in the same NTS1 background (Table 1), but
there are different modiﬁcations in the Nag36k and GW5 derivatives
used for puriﬁcation and crystallisation, which therefore have num-
bers to deﬁne the tags and deletions in the construct.
2.2. Thermostability assays in detergent solution
Cell pellets from 2 ml of IPTG-induced bacterial cultures were
resuspended in lysis buffer containing DNaseI and lysozyme (freshly pre-
pared in H2O). After incubation for 15 min on ice, the respective deter-
gents were added to give a ﬁnal buffer composition of 50 mM Tris–HCl
pH 7.4, 200 mM NaCl, 5 mM MgCl2, 0.75 mg/ml lysozyme, 20 μg/ml
DNaseI, and detergent in a total volume of 500 μl. Glycerol was included
as indicated. The detergent mixtures used are listed in Table S9. The
samples were placed on a rotating mixer at 4 °C for 1 h. Cell debris and
non-solubilised material were removed by centrifugation and the
cleared lysates containing detergent-solubilised NTS1 were tested for
thermal stability in the +NT format [22]. For 1-point assays and thermal
denaturation curves, the lysates were diluted into assay buffer (TEBB:
50 mM Tris–HCl pH 7.4, 1 mM EDTA, 0.1% BSA, 0.004% bacitracin; or TN
buffer: 50 mM Tris–HCl pH 7.4, 200 mM NaCl; see Table S9) containing
10–12 nM [3H]NT and incubated up to 2.5 h on ice to allow [3H]NT bind-
ing to NTS1. Samples (120 μl aliquots) were exposed to different temper-
atures for the indicated amount of time and placed on ice. Separation of
receptor–ligand complex from free ligand (100 μl) was achieved by
centrifugation-assisted gel ﬁltration (spin assay) using QS-QM mini-
columns packed with Sephadex G50 (equilibrated in 50 mM Tris–HCl
pH 7.4, 1 mM EDTA, and 0.1% DDM) [22] or Bio-Spin 30 Tris columns
(equilibrated with RDB buffer: 50 mM Tris–HCl pH 7.4, 1 mM EDTA,
0.1% DDM, 0.2% CHAPS, and 0.04% CHS). Control reactions on ice were
recorded at the start and at the end of each denaturation experiment.
The percentage of activity remaining after heat exposurewas determined
with respect to the unheated control. Data of thermal denaturation curves
were analysed by nonlinear regression using a Boltzmann sigmoidal
equation in the Prism software. Individual experiments were conducted
as single data points.
2.3. Ala/Leu scanning mutagenesis
Wild-type NTS1 was subjected to alanine/leucine scanning muta-
genesis where each residue from I61 to T400, spanning all seven TM
helices, three intracellular and three extracellular loops, and the prox-
imal half of the C-terminus was mutated to alanine (if the original
amino acid was alanine, then it was mutated to leucine) [22]. All
340 single Nag mutants were tested for thermostability in the +NTreceded by the MBP signal peptide; TrxA, E. coli thioredoxin (S2-A109); ENLYFQS, Tev
p 3 deletion Δi3, ΔG275-E296; Nag36k, NTS1 with the thermostabilising mutations
E166A–G215A–L310A–F358A–V360A; amino acid residues are abbreviated in the
presence or absence of ICL3, or the nature of the C-terminal tag are indicated by the
[28] for additional details of the NTS1(624) wild-type construct.
diﬁcation End of NTS1 C-terminal tag
Y424 AAA-TrxA-GT-H10
Y424 AAA-TrxA-GT-H10
Y424 AAA-TrxA-GT-H10
Y424 AAA TrxA GT H10
R420 ENLYFQS-NNNNN-GGGSGGGS-EF-TrxA-GT-H10
K396 A-H10-GG
Y424 AAA-TrxA-GT-H10
K396 A-H10-GG
K396 A-H10-GG
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ple and quadruple Nag mutants.
NTS1(1937B)36k was subjected to alanine/leucine scanning mu-
tagenesis from K64 to S373, using in part the robotic platform of the
Protein Production Facility of the New York Consortium on Mem-
brane Protein Structure. Individual NTS1 mutants were expressed in
E. coli and tested for stability in the presence of [3H]NT using a
cell-based rather than a detergent-based assay. Speciﬁcally, 30 μl of
cell suspension was added to 120 μl TEBB buffer (50 mM Tris–HCl
pH 7.4, 1 mM EDTA, 0.1% BSA, 0.004% bacitracin) containing 12.5 nM
[3H]NT and placed on ice. After 2 h, 120 μl of the mixture was heated
for 30 min at 57.5 °C and then quickly returned to ice. Separation of
bound from free ligand was achieved by rapid ﬁltration of 100 μl of
the mixture through GF/B glass ﬁbre ﬁlters (Whatman) pretreated
with polyethyleneimine [28]. A sample kept on ice throughout was
used as the unheated control. The receptor survival was recorded as a
percentage of [3H]NT binding relative to its respective control. The
heat test was conducted once for all mutants, and repeated 2–3 times
for promising candidates.
2.4. Puriﬁcation of NTS1(2088)GW5
NTS1(2088)GW5 was expressed in E. coli (100 l culture) in a bacte-
rial fermentor as described previously [28]. For the puriﬁcation, all steps
were performed at 4 °C or on ice. E. coli cells (200 g) were resuspended
in buffer (50 mM Tris pH 7.4, 200 mM NaCl, and 5 mM MgCl2)
supplemented with DNase I (ﬁnal concentration 4 μg/ml), protease in-
hibitors (leupeptin at 0.5 μg/ml, pepstatin A at 0.5 μg/ml, AEBSF at
100 μM) and NT (5 μM). Cells were lyzed using an Emulsi-ﬂex
homogeniser (Avestin, 3 passes at 15 K–20 K psi). After addition of
NaCl to a ﬁnal concentration of 0.5 M, the sample was centrifuged
(45Ti rotor, 40,000 rpm, 45 min, 4 °C, Optima L90K, Beckman). The
membrane pellet was resuspended in 600 ml of buffer containing NT
and receptors were extracted by drop-wise addition of a 5% DM
(n-decyl-β-D-maltopyranoside)/0.5% CHS (cholesteryl hemisuccinate)
solution. The ﬁnal volume was 780 ml containing 50 mM Tris–HCl
pH 7.4, 30% glycerol, 200 mM NaCl, 1% DM/0.1% CHS and 2.5 μM NT.
After 15 min, the sample was sonicated (20 min, Misonix sonicator
3000 with 1/2-inch ﬂat tip, 1 s on, 2 s off, output level 4) and allowed
to stir for an additional 20 min. The sample was clariﬁed by centrifuga-
tion (45Ti rotor, 40,000 rpm, 1 h, Optima L90K, Beckman), adjusted
with imidazole to a ﬁnal concentration of 20 mM, and then passed
through a 0.2 μm ﬁlter (Stericup). Next, the sample was loaded at a
ﬂow rate of 1 ml/min onto 20 ml Talon resin packed into an XK26 col-
umn (GE Healthcare) equilibrated with buffer A (50 mM Tris pH 7.4,
30% glycerol, 200 mM NaCl, 20 mM imidazole, 1 μM NT, 0.1% DM/
0.01% CHS). After washing with 10 column volumes of buffer A,
NTS1(2088)GW5 was eluted with buffer B (50 mM Tris, pH 7.4, 30%
glycerol, 200 mM NaCl, 200 mM imidazole, 1 μM NT, 0.1% DM/0.01%
CHS). Fractions containing NTS1(2088)GW5 (13 ml) were pooled and
NT (10 μM) was added. The puriﬁed NTS1(2088)GW5 fusion protein
was incubated with Tev protease (0.25/1 M/M Tev protease/NTS1 fu-
sion protein, 2 h at room temperature), concentrated to 5 ml (YM50
centriprep, 1500 ×g, 4 °C) and loaded onto a 16/60 Superdex 200
column equilibrated in 50 mM Tris pH 7.4, 5% glycerol, 500 mM NaCl,
1 mM EDTA, 1 μM NT, 0.25% n-nonyl-β-D-glucoside, 0.02% azide
(0.2 ml/min, 1 ml fractions) to separate cleaved NTS1-GW5 from MBP
and Tev protease. Selected fractions were analysed by SDS-PAGE and
Amido Black analysis.
3. Results
3.1. Identiﬁcation of thermostabilising point mutations
In our previous work on NTS1 [22], 340 point mutants were
constructed throughout the NTS1 cDNA, with each residue changedto either alanine or leucine (if the residue was already an alanine).
Two assays were used to test for thermostability. In the −NT assay,
mutants were screened by heating detergent-solubilised receptor in
the absence of ligand for 30 min, quenched on ice and the amount
of remaining functional receptor determined by using a [3H]NT ligand
binding assay. The best 137 mutants that showed stability similar to
or better than wild-type receptor were then assayed using the +NT
assay, where the heating step was performed in the presence of
[3H]NT. The best mutants from each assay were then combined to
make NTS1-7m [22].
In order to develop an NTS1 mutant with higher thermostability
than wild-type NTS1 and with better properties upon puriﬁcation
than NTS1-7m, we reasoned that only a single conformation should
be selected for i.e. the neurotensin-bound form. Therefore, the ther-
mostability of the NTS1 mutants in the unliganded state was ignored.
This meant that 203 mutants, which had not been assayed in the
+NT format, now needed to be investigated so this was the ﬁrst
step in this new work. Assays were performed exactly as described
previously by solubilising the E. coli-expressed receptors in a mixture
of dodecylmaltoside (DDM), CHAPS, cholesteryl hemisuccinate (CHS)
and glycerol and then heating the unpuriﬁed receptors in the pres-
ence of NT for 30 min at 37 °C [22]. The amount of each NTS1 mutant
remaining was then compared to the amount of the same mutant
present in the unheated solubilised control, and the percentage of re-
ceptor still active after heating calculated. These data, in combination
with the previous thermostability for the other 137 mutants, identiﬁed
68mutants thatwere of similar or better stability than thewild-type re-
ceptor in the presence of NT. These were then re-assayed under more
stringent conditions (+NT assay, 30 min at 40 °C) after solubilisation
in DDM that contained a lower percentage of glycerol and in the ab-
sence of CHAPS and CHS in order to more accurately differentiate the
degree of stabilisation (see Materials and methods). The 16 most
thermostabilising mutants (Table S1) were then chosen for further
work. Of these 16 mutants, 7 had been identiﬁed previously as being
more stable than wild-type receptor in the +NT assay and at least as
stable as wild-type NTS1 in the −NT assay. The remaining 9 mutants
were not previously used, because they were all less stable than the
wild-type NTS1 in the−NT assay (Fig. 1).
3.2. Construction and analysis of double mutants
There are 120 combinations of pair-wise mutations that are possi-
ble from the 16 most thermostable point mutations [16!/(14!*2!)].
All possible combinations were made, except for G306A/L310A, for
which the mutagenesis never worked, and these 119 mutants were
then expressed and tested for thermostability. A theoretical stability
score was determined from the sum of the stabilities of each point
mutant present i.e. if mutants A and B had experimentally determined
stabilities of 150 and 200, respectively, the theoretical score for mu-
tant A+B was 350. In theory, it would have been possible to convert
the measured stabilities, which are expressed here as a score relative
to a control, to an energetic term, if a few assumptions are made.
However, we have opted to leave them unchanged to provide a
clear methodology for anyone wishing to repeat this work on other
GPCRs. Comparison of the measured stability with the theoretical sta-
bility score for all the double mutants (Fig. 2) identiﬁed only one dou-
ble mutant with a stability close to the apparent sum of the stabilities
of the single mutants (Q239A+L310A), with the vast majority of the
mutants showing stabilities less than the sum of their parts. In fact,
even the most stabilising single mutants can sometimes be combined
with other stabilising mutants to result in double mutants with
thermostabilities considerably less than that of the wild-type NTS1
(Fig. 2). However, the systematic combination of the mutations also
identiﬁed a considerable number of mutants that were more thermo-
stable than those generated previously [22]. This was likely due partly
to the completeness of the data set, but also, perhaps, to the more
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Fig. 1. Stability of NTS1 point mutations. The stability of 340 NTS1 point mutants was
determined using the +NT assay [22]. Unpuriﬁed E. coli-expressed NTS1 fusion protein
was solubilised in DDM/CHAPS/CHS and 30% glycerol, incubated with [3H]NT, and half
of the sample was heated for 30 min at 37 °C, then quenched on ice. The amount of
receptor-bound [3H]NT in the heated sample was compared to the remainder of the
sample kept on ice (unheated control). Data for the +NT assay are plotted against
the stabilities of the same mutants determined using the−NT assay [22]. The error as-
sociated with these measurements is +/− 20%. All measurements were normalised to
the stability of wild-type NTS1 (100%). The 68 most stable mutants in the +NT assay
were then re-assayed under more stringent conditions (0.13% DDM, 7% glycerol,
40 °C, 30 min, with [3H]NT bound; Table S1); the top 16 mutants are shown coloured
and labelled in the scatter plot: red, mutants used previously to derive NTS1-7m [22];
green, new mutants from this study.
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being selected for, which is obviously desirable for crystallisation.
The other factor that needed to be considered was the decrease in
functional expression levels upon combination of two stabilising mu-
tations (Table S2). Some pairs of mutations reduced expression levels
by over 100-fold which is clearly undesirable for protein production
for crystallisation trials. In addition, extremely low levels of functional
expression increased the error of the thermostability measurements.
For these reasons, only those mutants that expressed above 30 recep-
tors per cell were considered as potentially useful.1000
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Fig. 2. Stability of NTS1 double mutants. The 119 double mutants were expressed and
assayed for stability using the +NT assay (0.13% DDM, 7% glycerol, 47 °C, 30 min, with
[3H]NT bound). The measured stabilities are plotted against the theoretical stability de-
termined from the sum of the experimentally determined stabilities of the single mu-
tants. Data for the 119 double mutants made from the 16 most thermostable single
mutants are plotted either in black, red (double mutants containing the point mutation
A86L), green (double mutants containing the point mutation Q239) or blue (double
mutants containing the point mutation L310). Mutants plotted in grey are the double
mutants generated during the previous study [22].3.3. Construction and analysis of triple mutants
If we consider the number of combinations of 3 or 4 point mutants
per receptor chosen out of the 16 mutants used to make the double
mutants, 560 and 1820 combinations, respectively, there are clearly
too many mutants to be made and assayed using the approach
described here. Therefore a strategy was devised to reduce the num-
ber of combinations that needed to be made. The assumption made
was that if mutations A+B, B+C and A+C were all highly additive
in the double mutants, then the combination A+B+C would be
favourable. In contrast, if any of the 3 double mutants were poorly ad-
ditive, then it would be less likely that the triple mutant would be
highly stabilised. A theoretical score for each of the possible triple
mutants was therefore calculated from the sum of the stabilities mea-
sured for each of the double mutants represented in the triple mu-
tant. If double mutants showed low [3H]NT binding, they were not
included in this analysis. The scores were then sorted and the compo-
sition of the theoretical best 16 triple mutants compared (Table S3)
and the number of times each single mutant appeared within the
list was tabulated. Three mutations (A86L, Q239A and L310A) domi-
nated the list with 10 or more appearances, suggesting that these mu-
tations combined effectively with many different mutations. The next
most additive mutations were V160A, A316L and F358A (3 appearances
each), with E166A, G215A, G306A, V360A and N370A all appearing
once or twice. In contrast, ﬁve mutations out of the original 16 (H103A,
I260A, V313A, S362A and F380A) did not appear at all in the top 16 theo-
retical triple mutants, indicating that they were probably not so compat-
ible with other mutations.
All the top scoring 16 theoretical triple mutants were constructed,
along with 8 other mutants that included other thermostabilising
point mutations, but which were predicted to make slightly less sta-
ble triple mutants. Upon measuring the thermostability of the 24 tri-
ple mutants constructed, 14 out of the top predicted 16 had stabilities
at least 2.5 times greater (±10% error) than the standard chosen for
this particular assay (Nag22d), whereas only one out of the other
8 mutants (Nag35f) was this stable (Fig. 3). The Nag35f mutant
contained the favourable Q239A+L310A mutations. Out of 53 triple
mutants constructed in the previous study [22] only 4 were more sta-
ble than Nag22d. Comparison of the measured stabilities of the triple
mutants with the theoretical scores, based upon the sum of stabilities
of the double mutants, showed a better correlation than was ob-
served for the double mutants (Figs. 3). However, the correlation
was still not perfect (r2=0.44), necessitating the construction and
assaying of multiple mutants to ensure the optimal combination
was found.
The apparent denaturation temperature (Tm) of 11 triple mutants
was determined after solubilisation in decylmaltoside (Table S3),
which is a slightly harsher detergent than dodecylmaltoside. The
most stable triple mutant was Nag34a that contained the mutations
A86L+L310A+Q239A and had an apparent Tm value of 47 °C. All
the other mutants tested had Tm values between 43 and 45 °C, al-
though the order was different from that predicted from the theoret-
ical triple mutant scores.
3.4. Construction and analysis of quadruple mutants
Quadruple mutants were designed by adding the extra mutation
selected from V160A, E166A, G215A, A316L, F358A or V360A to
each of the 4 best triple mutants Nag34a, 34j, 34l, and 34o based on
the apparent Tm measured in DM. Fourteen quadruple mutants
were synthesised and tested for stability in comparison to Nag34a
(Fig. 4 and Table S4). In order to make the assay more discriminatory,
assays were performed on octylglucoside-solubilised receptors heated
for 1 h in the presence of [3H]NT. Out of the fourteen mutants tested,
13 were more stable than the best triple mutant Nag34a. Three of
the quadruple mutants (Nag36b, 36 k and 36q) were all over 2.5
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Fig. 3. Stability of NTS1 triple mutants. (a) Twenty-four triple mutants were
constructed and assayed for stability using the +NT assay (0.3% DM, 7% glycerol,
45 °C, 30 min, with [3H]NT bound), which included the top 16 stable mutants (black
bars) as predicted from the sum of the measured stabilities of the three double mu-
tants composing each triple mutant. Other mutants tested (grey bars) are also
shown. Stabilities were normalised against the double mutant NTS1-22d (A86L/
Q239A). The number beneath each bar refers to the theoretical rank order position
for each mutant. The point mutations in each mutant are shown in Table S3. (b) Corre-
lation between the measured stability of triple mutants compared to their theoretical
stabilities (r2=0.44; no constraints applied).
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octylglucoside of 29 °C. One mutant did not express.
3.5. Identiﬁcation of additional thermostabilisation mutations in Nag36k
The deﬁned end-point for thermostabilisation of GPCRs is when
the receptor is sufﬁciently stable to form well-ordered crystals that
diffract well enough to allow structure determination. However, it is0
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Fig. 4. Stability of NTS1 quadruple mutants. Fourteen quadruple mutants were
constructed and their stability determined (0.8% OG, 45 °C, 1 h, with [3H]NT bound).
The stabilities were normalised against the stability of NTS1-34a (100%). The dotted
line represents 2.5-fold improvement in stability compared to NTS1-34a.clear that further stabilisation of an already thermostabilised receptor
is feasible [29,30] and also desirable, because better quality crystals
may be produced from more stable proteins. Therefore, whilst Nag36k
was being expressed and puriﬁed, further stabilisation of the mutant
was performed by subjecting the most stable quadruple mutant
Nag36k to alanine scanning mutagenesis in the +NT format. The origi-
nal Ala/Leu scanwas performed on anN-terminally truncated version of
NTS1 [22], but this scan used the Nag36k derivative NTS1(1937B)36k
(Table 1) that hadmost of the assumed ﬂexible portion of ICL3 removed
to aid crystallisation. The thermostability assay was simpliﬁed by using
E. coli cells rather than detergent-solubilised receptors (Fig. 5). Although
such an assay will select for NTS1 mutants with improved stability in a
lipid environment, we anticipated a parallel improvement in stability of
the detergent-solubilised receptor (see below). The top 12 most
stabilising mutations identiﬁed by Ala/Leu scanning mutagenesis
(Table S5) contained 4 mutations (G215A, Q239A, F358A, and S362A)
that were previously identiﬁed using the +NT format (see Table S1)
and 8mutations that were new. Of particular interest was themutation
F358A, which had previously been identiﬁed as thermostabilising in
both the +NT and−NT thermostability assays [22]. Although this mu-
tation was not included in the three best quadruple mutants (Nag36b,
Nag36k, and Nag36q), F358A conferred the largest stability increase to
Nag36k (Table S5). The F358A mutant in wild-type NTS1 background
has been found to be constitutively active [31] and in combination
with E166A and L310A may have directly promoted an active-like
state of NTS1 [27]. Selectedmutations, including F358Awere combined
to generate the mutants GW1-GW6 (Table S6) and NTS1-GW5 was
found to be most stable, increasing the thermostability of NTS1-36k
by ~4 °C (Table S7). Of interest, the expression levels of all the GW1–
GW6 mutants remained at a similarly high level to the NTS1-36k
(Tables S5 and S6).3.6. Biochemical characterisation of NTS1-GW5
NTS1(1937B)GW5 (see Table 1 for nomenclature) contains the 6
thermostabilising mutations A86L1.54, E166A3.49, G215AECL2, L310A6.37,
F358A7.42 and V360A7.44 (superscripts are the Ballesteros–Weinstein
numbers [32]) that are located in the NTS1 transmembrane bundle (ex-
cept G215Awhich is located in ECL2). Hence the stabilising effect is likely
to reﬂect the properties of the receptor transmembrane core, but the
exact sequence context at the N- or C-termini of NTS1 might also100 200 300 400
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Fig. 5. Stability of 288 mutants generated by Ala/Leu scanning mutagenesis of
NTS1(1937B)36k. The NTS1 fusion protein containing 4 thermostabilising mutations
was subjected to Ala/Leu scanning mutagenesis. Each of the 288 mutants was
expressed in E. coli, the cells incubated with the agonist [3H]NT and then heated at
57.5 °C for 30 min (+NT stability test). Receptor survival was recorded as a percentage
of [3H]NT binding relative to its unheated control. The horizontal line denotes the
remaining activity of NTS1(1937B)36k after heating (33%±2% SE). Error bars (SD)
for selected repeat experiments are shown (n=2–4). The x-axis gives the position of
the mutated amino acid residues in NTS1.
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NTS1(2088)GW5 (Table 1) with NTS1(1937B)GW5, exploring the
effect of the C-terminal TrxA-H10 module and the lack of a linker be-
tweenMBP and NTS1 on the overall receptor stability. We found no dif-
ference in stability between these NTS1 constructs (Fig. 6). This
suggests that the gain in stability was a reﬂection of the properties of
the transmembrane bundle and that adjacent sequences did not con-
tribute to stabilisation. In addition, the presence or absence of ICL3 did
not change the stability of the thermostabilised receptor (compare
NTS1(2088)GW5 and NTS1(2132)GW5, Table 1 and Fig. 6). Although
NTS1(1937B)GW5 was selected for improved stability in a lipid envi-
ronment using E. coli cells (Tables S5 and S6, Fig. 5), subsequent stability
tests in detergent solution (Table S7, Fig. 6) revealed improved stability
conferred by the additional G215A and F358Amutations suggesting the
use of E. coliwith the GPCR still in its normal cellular lipid environment
as a convenient alternative to detergent-based thermostability assays.
NTS1(1937B)GW5 containsMBP at the receptor N-terminus and the
full-length receptor C-terminus followed by the TrxA-H10 tag (Table 1).
Such a construct is unlikely to crystallise because of the ﬂexibility of
these domains in respect to the NTS1 core. We therefore used
NTS1(2088)GW5 for puriﬁcation, which had a shortened C-terminus
and a protease cleavage site between MBP and the receptor. We
puriﬁed the receptor by immobilised metal afﬁnity chromatography
exploiting the C-terminal histidine tag. After incubationwith Tev prote-
ase and removal of theMBPmoiety, the puriﬁed cleavedNTS1 showed a
symmetrical size exclusion chromatography peak in the detergent
n-nonyl-β-D-glucoside (Fig. 7, Table S8) indicating that the species
was monodisperse and suitable for crystallisation.15
Fig. 7. Puriﬁcation of NTS1-GW5. The fusion protein NTS1(2088)GW5 was puriﬁed by
immobilised metal afﬁnity chromatography and incubated with Tev protease to cleave
MBP from NTS1. (a) Separation of cleaved NTS1-GW5 from MBP and Tev by size exclu-
sion chromatography. (b) SDS-PAGE gel (NuPAGE 4–12% Bis-Tris gel, Invitrogen, 1×
MES SDS buffer, stained with SimplyBlue) analysis of puriﬁed fractions: Lane 1,
Novagen Perfect Protein Markers (15–150 kDa); lane 2, Talon eluate containing the in-
tact NTS1(2088)GW5 fusion protein; lane 3, Tev protease digest of Talon eluate; lane 4,
size exclusion chromatography peak containing puriﬁed, cleaved NTS1-GW5; lane 5,
size exclusion chromatography peak containing MBP and Tev protease. 5–10 μg pro-
tein were loaded per lane. The calculated molecular masses of the NTS1(2088)GW5
fusion protein, cleaved NTS1-GW5, MBP and Tev protease are 81.1 kDa, 38.9 kDa,
42.3 kDa and 28.6 kDa, respectively.4. Discussion
Thermostabilisation of GPCRs is an effective approach to facilitate
their structure determination by X-ray crystallography and for a variety
of biophysical assays such as surface plasmon resonance (reviewed in
[6]). Currently the fastest and most successful strategy in terms of gen-
erating the most thermostable mutant containing the minimum num-
ber of mutations is to generate individual point mutations, test their
effect on receptor thermostability and then combine 4–6 mutations.
This strategy works equally well expressing the mutant receptors in ei-
ther E. coli [22–24,29,33] or in mammalian cells [21], and would also be
possible using yeast. Generating ~300 mutants, sequencing them and
testing their thermostability are straightforward and can be completed
in a fewmonths by an experienced researcher. However, combining the
mutations is more problematic given the 8008 combinations of 620
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Fig. 6. The stability of NTS1 mutants is not inﬂuenced by modiﬁcations at the N- and
C-termini. DM-solubilised receptors were incubated with the agonist [3H]NT and
then exposed to 50 °C for 30 min (+NT stability test). Receptor survival was
recorded as a percentage of [3H]NT binding relative to its unheated control. Error
bars represent the SD for repeat experiments (n=2–4).mutations out of a possible 16 [16!/(10!*6!)]. The work presented
here describes an exhaustive search for the best 4 mutations out of a
possible 16 single mutants (1820 combinations). First, 119 out of a pos-
sible total of 120 double mutants were constructed from the 16 most
thermostable single mutants and their thermostability determined.
What was surprising was the large variation in thermostability of the
double mutants, from totally unstable (no [3H]NT binding at 4 °C) to
virtually an additive effect between the two mutations. Interestingly,
there did not appear to be any mutant that showed a synergistic effect
between the two thermostable single mutations. Using the thermosta-
bility of these double mutants as a guide, it seemed to be easier to pre-
dict which mutations could be combined compared to when only the
data from the single mutations were considered, although the correla-
tion between the theoretical stability score and the measured stability
was still far from perfect (r2=0.44).
Of the 14 quadruple mutants constructed 9 showed similar stabili-
ties (within the error of the single-point thermostability assay, ±20%)
to the most stable mutant Nag36k, although one quadruple mutant
did not fold into a functional receptor. The three best quadruple mu-
tants (Nag36b, 36k, and 36q) all had the same apparent Tm upon
solubilisation in OG (28.6 °C, 28.7 °C and 28.8 °C). Thus the systematic
methodology produced a number ofmutantswith equally high thermo-
stability, although this necessitated the construction of 340 single
mutants, 119 double mutants, 24 triple mutants and 14 quadruple
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Fig. 8. A simpliﬁed strategy for the generation of optimally stable mutants suitable for
puriﬁcation and crystallisation. The graph shows idealised results from the combina-
tion of thermostable mutations in a hypothetical receptor, based on the additivity of
individual mutations. The dashed line represents mutations that are perfectly additive
based on a theoretical score versus the actual experimentally determined thermostabil-
ity (the wild-type and single mutants are placed on this line for clarity, even though it
is not possible to predict a theoretical stability). Step 1: The top 16 mutants from an
Ala/Leu scan are identiﬁed by thermostability assays of the detergent solubilised recep-
tor and the best mutant determined (A). Step 2: Mutant A is combined individually
with all the other 15 single mutations (B–P) and the best double mutant determined
(A–B). Note that only 6 other mutations are additive to mutant A (mutants C, E, L, M,
N, and P) that are close to the dashed line. Step 3: Mutant A–B is combined individually
with mutations C, E, L, M, N, and P and the best triple mutant established (A–B–L). Note
that only 3 othermutations (E, N, and P) are additivewith the doublemutant A–B. Step 4:
Mutant A–B–L is combined individuallywith mutations E, N and P and the best quadruple
mutant determined (A–B–L–E). Subsequent steps: if time and resources permits, itmay be
worth combining the optimally stable quadruple mutant with each of the other muta-
tions, but further iterations will probably result in relatively smaller improvements in
thermostability. At this stage, if a signiﬁcant further improvement in thermostability is re-
quired, a completely new scanningmutagenesis procedure performed onmutant A–B–L–
E may be contemplated, as this has also been shown to be effective in identifying new
thermostabilising mutations.
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expression and determination of stability.
Could the optimally stable quadruple mutants have been obtained
without making so many mutants in total? One successful strategy
(Fig. 8) that was used on the A2AR (after this work was completed)
was to take the most thermostable single mutant, combine it with
each of the next 15 most stable mutants and then test their thermo-
stability [24]. The most thermostable double mutant was then com-
bined with the other 14 single mutants (provided they gave good
thermostability with the two single mutations in the double mutant)
to make a triple mutant and the process repeated to make a quadru-
ple mutant. So, if we had used this process for the thermostabilisation
of NTS1, would we have obtained the same thermostable quadruple
mutants? From Table S1, it would be apparent that F358A would be
the most desirable starting mutation as it is the most thermostable,
but its expression is markedly decreased which would reduce its de-
sirability as the ‘best’ mutation (the receptor has to be puriﬁed at
some stage for crystallisation). A86L is the next best choice, and if
this was taken through the above process using the results from Ta-
bles S2, S3 and S4 then the ﬁnal quadruple mutant would have
been A86L–E166A–L310A–V360A i.e. Nag36k, one of the three most
thermostable quadruple mutants found. This would have involved
making only an additional 24 mutations on top of the 340 single
mutants originally constructed (Fig. S1). However, the caveat with
this gedanken experiment is that some of the combinations of triple
mutants (A86L-L310A plus either G306A or H103A) and quadruplemutants (A86L-L310A-V360A plus either A316L or F358A) were
untested in this work, so it may have been possible to make an even
more thermostable quadruple than Nag36k. If this gedanken experi-
ment is repeated starting with F358A, the most desirable double mu-
tant would have been F358A–A316L, but unfortunately none of the
triple mutants constructed in the present work contained this pair
of mutations, so further speculation is not possible. However, the evi-
dence available suggests that the systematic combination of mutations
as described in Fig. 8 is an efﬁcient and rapid method for obtaining
the best thermostable mutant out of a given set of thermostabilising
point mutations. To give an idea of the time this would take starting
with a new receptor, we estimate that an experienced postdoctoral
worker could perform alanine scanning mutagenesis with the thermo-
stability assays and make a stable receptor containing 6 thermostable
mutations in about 6 months, providing that the thermostability assay
has already been developed.
The quadruple mutant NTS1-Nag36k was further stabilised by
performing a complete Ala/Leu scan throughout the receptor and
combining two of the mutations to improve the thermostability by
an additional 4 °C. The single mutants detected by the screening pro-
cedure were interesting from two perspectives. First, the new proce-
dure based upon heating NTS1 mutants in intact E. coli, i.e. the
receptor was in the lipid bilayer rather than in detergent solution, iden-
tiﬁed 4 thermostabilising mutations that had already been shown to be
thermostabilising, including F358A. This validates the methodology,
which has the important advantage of being able to process mutants
at a very high throughput because the assays use glass ﬁbre ﬁlters rath-
er than gel ﬁltration spin columns. Second, 8 newmutations were iden-
tiﬁed. This has been observed before with both the β1AR and A2AR
where re-scanning through a thermostable mutant identiﬁed muta-
tions different from those found in the ﬁrst screen on the wild-type re-
ceptor [21,29]. This is probably to be expected, because the mutated
receptors clearly have different properties to the wild-type receptors
and therefore different thermostabilising mutations will be needed to
stabilise them further. There was insufﬁcient time on this project for
an exhaustive trial of different combinations of these new mutations.
However, it is evident from the behaviour of the thermostabilised
receptor that contains the 6 optimal thermostabilising mutations,
NTS1-GW5, that they have conferred sufﬁcient stability for the receptor
to be puriﬁed as a homogeneous monodisperse preparation in NG,
which is a remarkably harsh detergent that cannot be used to purify
wild-type NTS1 in a monodisperse state. These results are analogous
to the thermostabilisation of the A2AR in an agonist-bound conforma-
tion [24], which eventually led to its structure determination at 2.6 Å
resolution [16]. Similarly, a construct based on NTS1-GW5 yielded ex-
cellent crystals that resulted in its structure being determined to 2.8 Å
resolution [27].
The systematic approach we advocate for the identiﬁcation and
combination of thermostabilising mutations is different from the
evolution-based methodology proposed by Plückthun and co-workers
[34–36]. The basis of their selection procedure is the increase in expres-
sion of some thermostable mutants compared to the wild-type receptor,
which allows an iterative procedure based on ﬂuorescence-activated
cell sorting (FACS) after binding a ﬂuorescent ligand. This does result in
improved expression of the receptor in the host cell (E. coli) and there is
an improvement in thermostability. Of the top 16 thermostable muta-
tions identiﬁed in this work (Table S1), only A86L, H103D, I260A and
F358A were also identiﬁed by FACS-based screening [34,36]. It is also
interesting to compare the thermostabilising mutations in NTS1-
GW5, which can be puriﬁed readily in a monodisperse state in
harsh detergents, with NTS1-7m that aggregates badly upon
puriﬁcation and was unsuitable for crystallography [22]. NTS1-7m
contained the thermostabilising mutations A86L–I260A–F342A–F358A
and NTS1-GW5 contained A86L–E166A–G215A–L310A–F358A–V360A.
Both thermostable mutants contained A86L–F358A, but NTS1-7m also
contained I260A–F342A that were not included in NTS1-GW5. F342A
1300 Y. Shibata et al. / Biochimica et Biophysica Acta 1828 (2013) 1293–1301was not in the top 16 most thermostable single mutations in the current
work and so was not included in the construction of double mutants.
I260A was included in the construction of double mutants, but it was
found to be poorly additive in comparison with other mutations and
therefore it was not used in the construction of the triple mutants.
The differences between the mutations present in NTS1-7m and
NTS1-GW5 and their vastly different properties during puriﬁcation
highlights the importance of carefully determining which mutations
should be combined. In theory, additional criteria could be included
in the screening procedure applied to the mutants to improve the
likelihood of obtaining a receptor mutant that does not aggregate.
For example, all the mutants could be screened in parallel by
ﬂuorescence-detection size exclusion chromatography [37] to ex-
clude those mutants that aggregate in detergent solution. In addition,
all the mutants could be screened for their ability to activate G pro-
teins, so that the optimally stable mutant shows wild-type levels of
agonist-induced G protein activation, which is not the case for both
NTS1 and A2AR stabilised in agonist-bound conformations (see [6]
for further discussion). However, both of these strategies would re-
quire substantial investment of time and resources during the
thermostabilisation procedure. In contrast, the comprehensive data
on double mutants presented here showed that it was only necessary
to consider those mutations that were most additive to construct a
thermostable mutant ideal for crystallisation. A simple rationale for
why combining only the additive mutants was successful, is perhaps
because they stabilise the same or a very similar 3-dimensional struc-
ture of the receptor, although this remains to be tested. Those muta-
tions that were not additive presumably stabilised subtly different
conformations and were therefore antagonistic. The simpliﬁed strate-
gy presented here for combining point mutations is possible by test-
ing only a small number of mutant combinations and will generate
receptor mutants ideal for puriﬁcation, crystallisation and structure
determination.Contributors
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